Author:
Wu Yuling,Pan Nana,An Yi,Xu Mengyuan,Tan Lijuan,Zhang Lijuan
Abstract
The incidence of myocardial infarction (MI) increases every year worldwide. Better diagnostic and prognostic biomarkers for clinical applications are the consistent pursuit of MI research. In addition to electrocardiogram, echocardiography, coronary angiography, etc., circulating biomarkers are essential for the diagnosis, prognosis, and treatment effect monitoring of MI patients. In this review, we assessed both strength and weakness of MI circulating biomarkers including: (1) originated from damaged myocardial tissues including current golden standard cardiac troponin, (2) released from non-myocardial tissues due to MI-induced systems reactions, and (3) preexisted in blood circulation before the occurrence of MI event. We also summarized newly reported MI biomarkers. We proposed that the biomarkers preexisting in blood circulation before MI incidents should be emphasized in research and development for MI prevention in near future.
Funder
National Natural Science Foundation of China
Subject
Cardiology and Cardiovascular Medicine
Reference155 articles.
1. Global, regional, national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015;Vos;Lancet,2016
2. Fourth universal definition of myocardial infarction (2018);Thygesen;Circulation,2018
3. High-sensitivity cardiac troponin and the universal definition of myocardial infarction;Chapman;Circulation,2020
4. Discovery of potential plasma protein biomarkers for acute myocardial infarction via proteomics;Xu;J Thorac Dis,2019
5. Biomarkers in acute myocardial infarction: current perspectives;Aydin;Vasc Health Risk Manag,2019
Cited by
49 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献